Novo Nordisk's POSEIDON study of 18,904 patients across 18 countries found that 40% of people with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or heart failure have cardiovascular inflammation. This inflammation, measured by high-sensitivity C-reactive protein (hsCRP), is a key independent risk factor for heart attacks and strokes despite standard treatments controlling cholesterol, blood pressure, and blood sugar. The findings highlight a major gap in cardiovascular care and support the need for new therapies targeting inflammation to reduce residual cardiovascular risk. The study was presented at the 94th European Atherosclerosis Society Congress and underscores the importance of inflammation as a driver of cardiovascular disease progression and risk.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
